Investment Rating - The report maintains a positive investment rating for leading companies in the media and internet sector, particularly recommending companies such as Shenzhou Taiyue, Southern Media, and Tencent Holdings [1][2]. Core Insights - The report emphasizes that leading companies in the gaming sector are undervalued, and an upcoming wave of AI applications is expected to drive growth [1]. - The media sector has shown resilience, with a year-to-date increase of 28.21%, ranking 9th among all sectors [6]. - The gaming industry is projected to maintain high growth, with key companies expected to have valuations below 15 times earnings, indicating a strong safety margin [6]. - The film industry is anticipated to experience a significant box office recovery due to the release of major films in November and December [6]. - AI applications in the film industry, particularly in AI animation, are seen as a rapidly monetizable direction [6]. Industry Overview Market Performance - The media industry index decreased by 1.44% in the past week, ranking 23rd among all industries [12]. - The report highlights the performance of individual stocks, with notable increases in companies like Xiangyuan Cultural Tourism and Lianchuang Shares [15]. Gaming Sector - The gaming sector is highlighted for its potential, with companies like Century Huatong and Giant Network expected to perform well in the upcoming year [6]. - The report notes that the gaming industry is likely to see breakthroughs in AI applications, enhancing growth prospects [6]. Film Sector - The report identifies a strong lineup of films for the end of the year, which is expected to boost box office revenues significantly [19]. - Major films such as "Demon Slayer" and "Avatar 3" are anticipated to drive ticket sales [6]. Key Data Points - The report provides detailed statistics on the performance of various segments within the media industry, including box office rankings and viewership ratings for television dramas and variety shows [19][25][32]. - The top-grossing mobile games in China are dominated by Tencent, with "Delta Force" leading the iOS sales chart [36]. Book Publishing Sector - The report includes data on the best-selling books in various categories, indicating trends in consumer preferences [38][39]. This summary encapsulates the key insights and data points from the industry report, focusing on the investment landscape and performance metrics across different sectors within the media and internet industry.

Investment Rating - The report gives a "Strong Buy" rating for the company [2]. Core Views - The PD-(L)1/VEGF dual antibody is positioned as a core drug for next-generation immuno-oncology treatments, with the SSGJ-707 molecule showing unique design and early clinical data indicating its potential as a best-in-class (BIC) candidate. The collaboration with Pfizer, involving an upfront payment of $1.4 billion and potential milestone payments of up to $4.8 billion, reflects the recognition of SSGJ-707's potential and the company's R&D capabilities [1][8][48]. - The company's financial performance is stable, with a well-structured product pipeline and strong long-term growth drivers [1][8]. Summary by Sections Company Overview - Established in 1993, the company is a leading biopharmaceutical firm in China, focusing on R&D, production, and sales of biological drugs. It has developed a rich product and pipeline portfolio across various therapeutic areas, including nephrology, oncology, autoimmune diseases, and dermatology [13][16]. Oncology Pipeline - The SSGJ-707 is expected to become a cornerstone in global cancer immunotherapy, with multiple first-in-class (FIC) molecules entering clinical stages. The collaboration with Pfizer is a significant milestone, with substantial financial backing and a strategic focus on expanding clinical trials [1][8][37]. - Clinical data for SSGJ-707 shows promising efficacy and safety profiles, with high overall response rates (ORR) in various cancer types, indicating its potential to address unmet medical needs in oncology [1][8][37][38]. Autoimmune Pipeline - The company has several pipelines nearing commercialization, with notable advancements in clinical trials for various autoimmune treatments. The IL-17A monoclonal antibody SSGJ-608 and IL-1β monoclonal antibody SSGJ-613 have received NDA acceptance, indicating progress towards market entry [8][19]. Commercialization Capability - The company demonstrates strong commercialization capabilities, with core products maintaining high market shares. The flagship product, TPIAO, is expected to generate significant revenue, supported by new indications and stable pricing strategies [8][19][30]. - The company is also expanding its product portfolio in the erythropoiesis-stimulating agent market, maintaining a leading position despite competitive pressures [8][19]. Financial Projections - Revenue projections for 2025-2027 are estimated at 185.2 billion, 115.5 billion, and 117.8 billion CNY, respectively, with corresponding net profits of 97.7 billion, 37.2 billion, and 32.8 billion CNY. The report anticipates a significant increase in revenue in 2025, followed by a decline in subsequent years [7][8].

Investment Rating - The report maintains a "Recommended" rating for the industry, indicating a positive outlook for the sector's fundamentals and expected performance exceeding the benchmark index [5]. Core Insights - The company, Hesai (HSAI.O), reported a revenue of 795 million yuan for Q3 2025, representing a year-over-year increase of 47.5%, marking six consecutive quarters of growth [2][23]. - The company has adjusted its full-year guidance, projecting total revenue for 2025 to be between 3 billion to 3.2 billion yuan, with a GAAP net profit forecast of 350 million to 450 million yuan [3][25]. - The company achieved a significant milestone by delivering over 1 million laser radars in the first three quarters of 2025, maintaining the leading market share in the ADAS sector [3][20]. Summary by Sections Revenue Performance - In Q3 2025, the company achieved a revenue of 795 million yuan, a 47.5% increase year-over-year, driven by the standardization of onboard laser radar and expansion in the robotics sector [2][24]. - For the first three quarters of 2025, total revenue reached 2.027 billion yuan, reflecting a 49.3% year-over-year growth [2]. Profitability Metrics - The gross margin for Q3 2025 was reported at 42.1%, slightly down from the previous year, but expected to remain around 40% in Q4 [2][24]. - The GAAP net profit for Q3 2025 was 256 million yuan, marking a historical high and surpassing the annual profit target ahead of schedule [2][20]. Market Position and Delivery Volume - The company delivered 441,400 laser radars in Q3 2025, a year-over-year increase of 228.9%, with ADAS laser radar deliveries reaching 380,800 units [3][20]. - The company holds a dominant market share in the ADAS sector, with a reported market share of 46% as of August 2025, significantly higher than its competitors [3][20]. Future Outlook - For Q4 2025, the company expects net revenue to be between 1 billion to 1.2 billion yuan, with year-over-year growth projected between 39% to 67% [3][25]. - The company anticipates total laser radar deliveries for 2025 to reach approximately 1.6 million units, with expectations for 2026 to see deliveries between 2 million to 3 million units [3][25][28]. Strategic Developments - The company has secured significant contracts with major ADAS clients, with all models from its top two clients in 2026 expected to be equipped with Hesai laser radars [4][21]. - The successful IPO in September 2025 raised 614 million USD, marking the largest IPO in the laser radar industry, which will enhance the company's financial foundation and support future growth initiatives [20][22].

Investment Rating - The report maintains a "Strong Buy" rating for Yili Co., Ltd. (伊利股份) [3][5] Core Views - Yili Co., Ltd. emphasizes a strategy focused on quality leadership, horizontal expansion, and vertical upgrades, aiming for balanced growth and profitability while enhancing shareholder returns [2][4] - Despite short-term demand pressures, the company has stabilized its liquid milk market share, with other business segments performing well and continuous improvement in net profit margins [5] - The company plans to focus on the recovery of liquid milk, performance improvement under supply-demand balance, and new growth drivers from deep processing, health products, and overseas markets [5] Summary by Sections Company Overview - Yili Co., Ltd. held an investor day on November 18, 2025, where management discussed the five-year development plan, highlighting the potential for increased per capita consumption of dairy products in China [2] Financial Performance - The company expects earnings per share (EPS) of 1.76 CNY and 1.94 CNY for 2025 and 2026, respectively, with a valuation of 16.7X for 2025 [5] - The projected total revenue for 2025 is 116.53 billion CNY, with a slight increase of 0.6% year-on-year [6][14] Business Segments - Liquid Milk: The company is shifting from extensive growth to high-quality growth through product innovation and brand enhancement, aiming for positive growth ahead of the industry by 2026 [4][5] - Infant Formula: The "Golden Crown" brand has maintained over 15% compound growth in the past five years, with a target to achieve over 25% market share [4] - Deep Processing: The deep processing sector is rapidly developing, with significant market potential driven by consumption upgrades [4] International Expansion - Yili Co., Ltd. is committed to international growth, with targets for double-digit compound growth in markets like Indonesia and Thailand, and a 20% growth target in the Australian market [4] Shareholder Returns - The company has announced a dividend payout ratio of no less than 75% for the years 2025-2027, with a minimum cash dividend of 1.22 CNY per share for 2024 [4][5]

Investment Rating - The report maintains a "Strong Buy" rating for Pinduoduo (PDD.O) [2] Core Insights - Pinduoduo's Q3 2025 revenue reached 108.3 billion yuan, a year-over-year increase of 9%, with advertising revenue at 53.35 billion yuan, up 8%, slightly below expectations. Non-GAAP net profit was 31.4 billion yuan, a 14.3% increase year-over-year, exceeding expectations. The company plans to continue significant investments in its ecosystem, which may impact short-term profits but is expected to drive sustainable high-quality growth in the long term [1][4] - The company is optimistic about the long-term growth potential of its domestic business and overseas markets, despite short-term fluctuations in profits due to increased ecosystem investments and macroeconomic uncertainties [1][4] Financial Data Summary - For 2023, the total revenue is projected at 247.639 billion yuan, with a year-over-year growth of 90%. The net profit is expected to be 67.899 billion yuan, reflecting a 72% increase. The EPS (Non-GAAP) is projected at 6.79 yuan, with a P/E ratio of 18.9 [2][7] - The financial forecasts for 2024 to 2027 indicate continued growth, with total revenue expected to reach 557.912 billion yuan by 2027, and net profit projected at 162.547 billion yuan [2][5][7] Stock Performance - The stock has shown a 1-month absolute performance of 0.4%, a 6-month performance of 9.9%, and a 12-month performance of 10.0%. However, the relative performance over 12 months is down by 24.2% [4]

Investment Rating - The report maintains an "Add" rating for the company [3] Core Views - The company has shown signs of operational efficiency improvement, with Q3 revenue and profit beginning to recover after a challenging first half of the year [7] - The introduction of the "AI Private Network" strategy aims to transition traditional communication to intelligent collaboration, addressing the increasing demands for security, efficiency, and intelligence from commercial users [7] - Increased R&D investment is being made to tackle patent challenges and enhance the company's technological independence, with significant progress in proprietary communication technology standards [7] - Ongoing litigation may create uncertainty regarding profit levels, with potential financial implications from various legal cases [7] Financial Data and Valuation - For 2023, total revenue is projected at 56.53 billion, with a year-on-year growth of 0%. The operating profit is expected to be 2.03 billion, reflecting a decline of 43% [2][13] - The net profit attributable to the parent company is forecasted to be -3.88 billion in 2023, indicating a significant year-on-year decrease of 195% [2][13] - The company’s PE ratio is projected to be -55.1 for 2023, improving to 62.0 by 2025 [2][14] - The total assets are estimated at 118.20 billion for 2023, with a debt ratio of 48.9% [12][14] Stock Performance - The current stock price is 11.75 yuan, with a total market capitalization of 21.4 billion [3] - The stock has shown a relative performance decline of 60% over the past 12 months compared to the CSI 300 index [5] Shareholder Information - The major shareholder is Chen Qingzhou, holding a 39.2% stake in the company [3]

Investment Rating - The report maintains a "Recommended" rating for the industry [1] Core Views - The report highlights a return of inflation trading, with consumer goods showing a positive trend in performance [1][8] - The overall industry size is significant, with a total market capitalization of 18,186 billion and a circulating market capitalization of 16,721.2 billion [1] Summary by Sections Macroeconomic Analysis - Retail sales growth year-on-year is at 2.9%, with a slight recovery in October due to the holiday effect, showing a month-on-month increase of 0.16% [6] - The restaurant sector saw a year-on-year revenue increase of 3.8% in October, while jewelry sales surged by 37.6% [6][7] - Service retail sales grew by 5.3% year-on-year from January to October, indicating a gradual recovery in service consumption [7] Food and Beverage Sector - October inflation data exceeded expectations, with both CPI and PPI showing improvements, suggesting a potential recovery in profitability for the food and beverage sector [8] - Companies like Haidilao and Anjuke are expected to perform well due to improved demand and operational strategies [9][10] Textile and Apparel Sector - The textile manufacturing sector is experiencing stable overseas demand, with major brands like NIKE showing signs of recovery [12] - Recommendations include focusing on leading manufacturers with optimized order structures and production efficiency [12] Tobacco Sector - The report recommends companies like Smoore International and China Tobacco Hong Kong, highlighting their stable growth and market positioning [16] Home Appliances Sector - The report suggests focusing on leading white goods manufacturers like Midea Group, which has shown stable operational performance [17] Retail and E-commerce - The report notes a significant increase in e-commerce sales during the Double Eleven shopping festival, with a total sales growth of 14.2% [24] - Companies like JD.com are expected to maintain robust growth, with a projected non-GAAP net profit of 318 billion for 2025 [25] Pharmaceutical Sector - The report emphasizes the importance of innovation in the pharmaceutical industry, recommending companies like Innovent Biologics and 3SBio for their strong project pipelines [27] Agriculture Sector - The report indicates a rapid reduction in sow production capacity, suggesting a potential increase in pig prices in 2026 [28]

银行研思录 26 资本和风险分类新规过渡期结束压力测算 总量研究/银行 2023 年 2 月发布的《商业银行金融资产风险分类办法》正式将非信贷资产也纳 入五级分类的计量范围，随后 2023 年 11 月 1 日发布的《商业银行资本管理办 法》，对银行信贷及非信贷资产拨备计提，以及超额拨备/拨备缺口的资本计量 提出了明确的要求，上述规定的过渡期将于 2025 年 12 月 31 日结束。 本期研思录复盘《风险分类新规》和《资本新规》的风险计量和拨备计提相关 监管规定，并基于此对 56 家 A、H 股上市银行的拨备计提达标压力进行测算， 供投资者参考。 证券研究报告 | 行业深度报告 2025 年 11 月 18 日 2、《银行股息率排名与中期分红进 度梳理—银行研思录 25》2025-11-14 3、《M1 增速开启下行—2025 年 10 月金融数据点评》2025-11-13 王先爽 S1090524100006 wangxianshuang@cmschina.com. cn 文雪阳 S1090524110001 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票 ...

Group 1 - The core viewpoint of the report indicates that insurance funds continue to flow into the stock market, while uncertainty regarding the Federal Reserve's interest rate cuts has increased [2][4][55] - As of the end of Q3, the total balance of insurance funds reached 37.5 trillion yuan, reflecting a year-to-date growth of 12.6% and a quarter-on-quarter increase of 3.4% [4][8] - The proportion of equity assets held by insurance funds has risen to a historical high of 14.85%, with total equity assets amounting to 5.56 trillion yuan [4][10] Group 2 - In terms of liquidity, the report notes that the net inflow of funds in the secondary market has narrowed, with a decrease in financing balance and net selling of financing funds amounting to 8.2 billion yuan [4][25] - The report highlights that the net inflow of ETFs was 123.1 billion yuan, while the issuance of new equity public funds decreased [4][25] - The report identifies a preference for sectors such as power equipment, basic chemicals, and non-ferrous metals, which saw significant net inflows from various funds [44][45] Group 3 - The report discusses the impact of recent hawkish signals from Federal Reserve officials, which have led to a downward adjustment of interest rate cut expectations for the year [55][56] - It emphasizes that the market's risk appetite is influenced by the lack of key economic data due to the government shutdown, creating a need for clearer signals to reduce uncertainty [2][55] - The report also notes that the VIX index has risen, indicating a decline in market risk appetite [35]

Investment Rating - The report maintains a "Strong Buy" rating for the company [3]. Core Insights - The company is the world's second-largest producer of lithium hexafluorophosphate, with a strong integrated layout and leading technology in crystalline hexafluoride. The demand for lithium batteries is expected to continue growing, leading to a significant rebound in hexafluoride supply and demand, with prices increasing over 170% from the bottom. This business is projected to contribute significantly to profits next year [1][7]. - The cylindrical battery business is starting to gain traction, with the company expected to become a key player in this field, contributing positively to profitability [1][27]. - The company has a comprehensive advantage in the hexafluoride sector, with a complete industrial chain from raw materials to lithium batteries, which enhances cost advantages [10]. Summary by Sections 1. Comprehensive Advantages in Hexafluoride - The company has established a complete industrial chain for hexafluoride production, significantly reducing raw material costs [10]. - It is the first domestic company to achieve breakthroughs in high-purity crystalline hexafluorophosphate technology, simplifying operations and improving raw material utilization [10][7]. 2. Reversal in Hexafluoride Supply and Demand - The hexafluoride market is experiencing a reversal in supply and demand, with prices rising sharply due to increased demand from the lithium battery sector. The average price has surged from 50,000 yuan/ton to over 150,000 yuan/ton [13][14]. - The company has a diverse customer base, with less than 30% of revenue coming from its top five customers, allowing it to be more sensitive to price increases [14][13]. 3. Growth in Cylindrical Battery Business - The company has been developing its battery business for over a decade, focusing on cylindrical batteries, which are now seeing significant demand in various sectors [27]. - The company aims to achieve a shipment volume of over 10 GWh in 2025, with expectations to reach 20-30 GWh in subsequent years [27][28]. 4. Financial Projections - The company is expected to generate revenues of approximately 10.26 billion yuan in 2025, with a significant increase projected for 2026 and 2027 [33][32]. - The gross profit margin for the hexafluoride business is expected to improve significantly, with projections of 28% in 2025 and 41% in 2026 [32][33].